Of all the biochemical changes that occur with aging, what really matters? How can we use the incredible amount of health data available today to discover the best targets for interventions? In this episode, Kristen Fortney of BioAge talks with Gordon about the latest research in proteomics and metabolomics, the importance of muscle loss, and the challenge of measuring the right endpoints for effective treatment and regulatory approval.

Kristen Fortney is the co-founder and CEO of BioAge, a clinical-stage biotechnology company developing a pipeline of treatments to extend healthy lifespan by targeting the molecular causes of aging. The company uses its discovery platform, which combines quantitative analysis of proprietary longitudinal human samples with detailed health records tracking individuals over the lifespan, to map out the key molecular pathways that impact healthy human longevity. By targeting these pathways with a large and mechanistically diverse portfolio of drugs, BioAge is unlocking opportunities to treat and prevent diseases of aging in entirely new ways. Kristen’s scientific background is in aging biology and bioinformatics. She received her PhD in Medical Biophysics from the University of Toronto, followed by postdoctoral training at Stanford University, where she was a fellow of the Ellison Medical Foundation & American Federation for Aging Research.

Support the Show.